Sign up for our Free monthly newsletter
www.jashbotanicals.com \\ articles \ Natural Guide to Skin Health
1
2
3
4
5
6
7
8
Introductions Exercise Herbal Recommendations
Why Does the Skin Age? Environmental Toxins Diet Recommendations
Sunbeds - Your Ticket to Skin Cancer Dehydration Juicing and Your Skin
The Vitamin D Issue High Fat, Sugar, & Salt Physical Recommendations
Drugs, Smoking, & Alcohol What are you Putting on Your Skin?
References
Stress and Your Skin Nutrient Recommendations References (cont...)
Adequate Sleep Nutrient Recommendations (cont...)



References

  1. World Cancer Research Fund. Food, Nutrition and Cancer. Washington, DC: American Institute for Cancer Research, 1997.
  2. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002; 287:47-54.
  3. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333:1369-73.
  4. Smithells RW, Sheppard S, Schorah CJ. Vitamin dificiencies and neural tube defects. Arch Dis Child 1976; 51:944-50.
  5. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832-5.
  6. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-7.
  7. Federal Register. Food Standards: Amendment of Standards of Identity For Enriched Grain Products to Require Addition of Folic Acid. Final rule, 5 March 1996. Food and Drug Administration: Washington, DC, 1996.
  8. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-28.
  9. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160:422-34.
  10. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-50.
  11. Manson JE, Gaziano JM, Spelsberg A, et al. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Ann Epidemiol 1995; 5:261-9.
  12. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 2002; 13:120-6.
  13. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87:1767-76.
  14. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281:1632-1637.
  15. Carpenter KJ. The history of scurvy and vitamin C. Cambridge: Cambridge University Press, 1986.
  16. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 1999; 69:1086-107.
  17. Douglas RM, Chalker EB, Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2000:CD000980.
  18. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338:777-83.
  19. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23:560-9.
  20. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291:1999-2006.
  21. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004; 79:362-71.
  22. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328:1444-9.
  23. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-6.
  24. Rimm EB, Stampfer MJ. Antioxidants for vascular disease. Med Clin North Am 2000; 84:239-49.
  25. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447-55.
  26. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:154-60.
  27. Kris-Etherton PM, Lichtenstein AH, Howard BV, et al. AHA science advisory: antioxidant vitamin supplements and cardiovascular disease. Circulation 2004; 110:637-641.
  28. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005: 142(1):37-46. Published online Nov 10, 2004.
  29. Buring JE, Hennekens CH, for the Women's Health Study Research Group. The Women's Health Study: Rationale, background and summary of the study design. J Myocardial Ischemia 1992; 4:27-29 and 30-40.
  30. Hercberg S, Preziosi P, Briancon S, et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study--design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants. Control Clin Trials 1998; 19:336-51.
  31. Weber P. Vitamin K and bone health. Nutrition 2001; 17:880-7.
  32. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr 1999; 69:74-9.
  33. Booth SL, Tucker KL, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr 2000; 71:1201-8.
  34. Booth SL, Pennington JA, Sadowski JA. Food sources and dietary intakes of vitamin K-1 (phylloquinone) in the American diet: data from the FDA Total Diet Study. J Am Diet Assoc 1996; 96:149-54.
  35. Flendrie, M. Arthritis Research and Therapy, April 3, 2005. News release, BioMed Central. Candace Steele, director, global public relations, Wyeth Pharmaceuticals. Jim Bozikis, manager, pharmaceutical public affairs, Abbott Laboratories.
  36. D Gonzalez de Requena and others. Atazanavir Ctrough Is Associated with Efficacy and Safety: Definition of Therapeutic Range. Abstract 645. 12th CROI. February 22-25, 2005. Boston, MA.
  37. CDC and the National Foundation for Infectious Disease, "Update: Provisional Public Health Service Recommendations for Chemoprophylaxis After Occupational Exposure to HIV," MMWR Morb Mortal Wkly Rep, 1996, 45(22):468-80.
  38. Deeks SG, Smith M, Holodniy M, et al, "HIV-1 Protease Inhibitors. A Review for Clinicians," JAMA, 1997, 277(2):145-53.
  39. Hilts AE and Fish DN, "Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction," Am J Health Syst Pharm, 1998, 55:2528-33.
  40. "Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents, Panel on Clinical Practices for Treatment of HIV Infection," February 5, 2001. Available at: http://www.hivatis.org. Accessed February 14, 2001.
  41. Kakuda TN, Struble KA, and Piscitelli SC, "Protease Inhibitors for the Treatment of Human Immunodeficiency Virus Infection," Am J Health Syst Pharm, 1998, 55(3):233-54.
  42. Kaufman MB and Simionatto C, "A Review of Protease Inhibitor-Induced Hyperglycemia," Pharmacotherapy, 1999, 19(1):114-7.
  43. Kaul DR, Cinti SK, Carver PL, et al, "HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications," Pharmacotherapy, 1999, 19(3):281-98.
  44. McDonald CK and Kuritzkes DR, "Human Immunodeficiency Virus Type 1 Protease Inhibitors," Arch Intern Med, 1997, 157(9):951-9.
  45. Mueller BU, Smith S, Sleasman J, et al, "A Phase I/II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection," Int Conf AIDS, 1996, 11:37.
  46. "Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, Perinatal HIV Guidelines Working Group," January 24, 2001. Available at: http://www.hivatis.org. Accessed February 14, 2001.
  47. Rana KZ and Dudley MN, "Human Immunodeficiency Virus Protease Inhibitors," Pharmacotherapy, 1999, 19(1):35-59.
  48. Flendrie, M. Arthritis Research and Therapy, April 3, 2005. News release, BioMed Central. Candace Steele, director, global public relations, Wyeth Pharmaceuticals. Jim Bozikis, manager, pharmaceutical public affairs, Abbott Laboratories
  49. Davis DL, Dinse GE, Hoel DG. Decreasing cardiovascular disease and increasing cancer among whites in the United States from 1973 through 1987. JAMA 1994;271:431-437.
  50. Rogers SA. Diagnosing the tight building syndrome, Environ Health Perspect 1987;76:195-198.
  51. Godish T. Sick Buildings: Definition, Diagnosis, And Mitigation. Boca Raton, FL: Lewis Publications;1995.
  52. Cullen MR. Workers with Multiple Chemical Sensitivities. Occup Med 1987;2:655-661.
  53. Hileman B. Multiple Chemical Sensitivity. Chem Eng News 1991;69:26-42.
  54. Rea WJ. Chemical Sensitivity Vol. 1,2,3. Boca Raton, FL: Lewis Publications;1992, 1994, 1996.
  55. Chambers JE, Levi PE, ed. Organophosphates, Chemistry, Fate, and Effects. San Diego, CA: Academic Press;1992.
  56. Arlien-Soberg P. Solvent Neurotoxicity. Boca Raton, FL: CRC Press;1992.
  57. Luster MI, Rosenthal GJ. Chemical agents and the immune response. Environ Health Perspect 1993;100:219-226.
  58. Vial T, Nicolas B, Descotes J. Clinical immunotoxicity of pesticides. J Toxicol Environ Health 1996;48:215-229.
  59. Hueser G. Diagnostic markers in clinical immunotoxicology and neurotoxicology. J Occup Med Toxicol 1992;1:5-9.
  60. Rea WJ. Chemical Sensitivity Vol. 3. Boca Raton, FL: CRC Press;1996.
  61. EPA, Office of Toxic Substances. Broad scan analysis of the FY82 national Human Adipose Tissue Survey Specimens. EPA-560/5-86-035.
  62. Stehr-Green PA. Demographic and seasonal influences on human serum pesticide residue levels. J Toxicol Environ Health 1989;27:405-421.
  63. Adeshina F, Todd EL. J Toxicol Environ Health 1990;29:147-156.
  64. Jacobson JL, Humphrey HE, Jacobson SW, et al. Am J Public Health 1989;79:1401-1404.
  65. Wallace LA, Pellizzari ED, Hartwell TD, et al. Personal exposures, indoor-outdoor relationships, and breath levels of toxic air pollutants measured for 355 persons in New Jersey. EPA 0589.
  66. Gunderson EL. FDA Total Diet Survey, April 1982-April 1986, Dietary intakes of pesticides, selected elements and other chemicals. Food and Drug Administration, Division of Contaminants Chemistry, Washington, DC 20204.
  67. Kuhnlein HV, Receveur O, Muir DC, et al. Arctic indigenous women consume greater than acceptable levels of organochlorines. J Nutr 1995;125:2501-2510.
  68. Vial T, Nicolas B, Descotes, J. Clinical immunotoxicity of pesticides. J Toxicol Environ Health 1996;48:215-229.
  69. Rea WJ. Presentation at 13th International Symposium on Man and His Environment in Health and Disease. Dallas,TX 1995.
  70. Haschek WM, Rousseaux CG. Handbook of Toxicologic Pathology. San Diego, CA. Academic Press. 1991.
  71. Thrasher JO, Madison R, Broughton A. Immunologic abnormalities in humans exposed to chlorpyrifos: preliminary observations. Arch Environ Health 1993;48:89-93.
  72. Anderson HA, Lilis R, Selikoff IJ, et al. Unanticipated prevalence of symptoms among dairy farmers in Michigan and Wisconsin. Environ Health Perspect 1978;23:217-226.
  73. Broughton A, Thrasher JD. Chronic health effects and immunological alterations associated with exposure to pesticides. Comm Toxicol 1990;4:59-71.
  74. Vojdani A, Ghoneum M, Brautbar N. Immune alteration associated with exposure to toxic chemicals. Toxicol Ind Health 1992;8:239-253.
  75. Selgrade MK, Cooper GS, Germolec DR, Heindel JJ. Linking environmental agents to autoimmune disease. Environ Health Perspect 1999;107:S5811-S811.
  76. Wasserman M, Nogueira DP, Tomatis L, et al. Organochlorine compounds in neoplastic and adjacent apparently normal breast tissue. Bull Environ Contam Toxicol 1976;15:478-484.
  77. Mussalo-Rauhamaa H. Occurrence of beta-hexachlorocyclohexane in breast cancer patients. Cancer 1990;66:2124-2128.
  78. Falck F. Pesticides and polychlorinated biphenyl residues in human breast lipids and their relation to breast cancer. Arch Environ Health 1992;47:143-146.
  79. Wolff MS, Toniolo PG, Lee EW, et al. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 1993;85:648-652.
  80. Hunter DJ, Hankinson SE, Laden F, et al. Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 1997;337:1253-1258.
  81. Krieger N, Wolff M, Hiatt RA, et al. Breast cancer and serum organochlorines: a prospective study among white, black, and Asian women. J Natl Cancer Inst 1994;86:589-599.
  82. Davis JR, Brownson RC, Garcia R, et al. Family pesticide use and childhood brain cancer. Arch Environ Contam Toxicol 1993;24:87-92.
  83. Leiss J, Savitz D. Home pesticide use and childhood cancer: A case control study. Am J Public Health 1995;85:249-252.
  84. Claggett S. 2,4-D Information Packet. Northwest Coalition for Alternatives to Pesticides. 1990.
  85. Spirtas R, Stewart PA, Lee JS, et al. Retrospective cohort mortality study of workers at an aircraft maintenance facility. Br J Ind Med 1991;48:515-530.
  86. Anttila A, Pukkala E, Sallman M, et al. Cancer incidence among Finnish workers exposed to halogenated hydrocarbons, J Occup Environ Med 1995;37:797-806.
  87. Fleming L, Timmeny W. Aplastic anemia and pesticides, an etiologic association? J Occup Med 1993;35:1106-1115.
  88. Bethwaite PB, Pearce N, Fraser J. Cancer risks in painters: study based on the New Zealand Cancer Registry, Br J Ind Med 1990;47:742-746.
  89. Eriksson M, Karlsson M. Occupational and other environmental factors and multiple myeloma: a population based case-control study. Br J Ind Med 1992;49:95-103.
  90. Synder SH, D'Amato RJ. Predicting Parkinson's disease. Nature 1985;317:198-199.
  91. Calne DB, Langston JW, Martin WR, et. al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248.
  92. Lund B, Bergman A. Brandt I. Metabolic activation and toxicity of a DDT-metabolite, 3-methylsulphonyl-DDE, in the adrenal zona fasciculata in mice. Chem Biol Interact 1988;65:25-40.
  93. Colby HD. Chemical suppression of steroidogenesis. Environ Health Perspect 1981;38:119-127.
  94. Li MH, Hansen L. Enzyme induction and acute endocrine effects in prepubertal female rats receiving environmental PCB/PCDF, PCDD mixtures. Environ Health Perspect 1996;104:712-722.
  95. Leatherland JF. Changes in thyroid hormone economy following consumption of environmentally contaminated Great Lakes fish. Toxicol Ind Health 1998;14:41-57.
  96. Porterfield SP, Hendry LB. Impact of PCBs on thyroid hormone directed brain development. Toxicol Ind Health 1998;14:103-120.
  97. McLachlan JA. Estrogen pairings can increase potency. Science News 1996;149:356.
  98. Colburn T, Dumanski D, Myers JP. Our Stolen Future: Are We Threatening Our Fertility, Intelligence, and Survival – A Scientific Detective Story. NY, NY:Dutton; 1996.
  99. Leoni V, Fabiani L, Marinelli G, et al. PCB and other organochlorine compounds in blood of women with or without miscarriage: a hypothesis of correlation. Ecotoxicol Environ Saf 1989;17:1-11.
  100. Laino C. City air pollution linked to male infertility. Med Trib 1995; Nov:14.


1
2
3
4
5
6
7
8

Site Map Legal Disclaimer Privacy Statement
Disclaimer: None of the above statements have been evaluated or approved by the Food and Drug Administration or the American Medical Association. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider before using any herbal products.